Cefazolin Powder, For Solution
NDC Package 63323-237-10
Package Information
Cefazolin (cefazolin sodium) powders is cefazolin is an antibiotic used to treat a wide variety of bacterial infections. This formulation utilizes a powder, for solution delivery system. Marketed by Fresenius Kabi Usa, Llc, this product is identified by NDC 63323-237 and is authorized under FDA application ANDA065303.
Identification & Billing
- RxCUI: 1665050 - ceFAZolin 1 GM Injection
- RxCUI: 1665050 - cefazolin 1000 MG Injection
- RxCUI: 1665050 - cefazolin 1 GM (as cefazolin sodium) Injection
- RxCUI: 1665050 - cefazolin 1 GM Injection
- RxCUI: 1665052 - ceFAZolin 500 MG Injection
Clinical Specifications
- Intramuscular - Administration within a muscle.
- Intravenous - Administration within or into a vein or veins.
Regulatory & Marketing
Hierarchy Structure
- 63323 - Fresenius Kabi Usa, Llc
- 63323-237 - Cefazolin
- 63323-237-10 - 25 VIAL in 1 CARTON / 3 mL in 1 VIAL (63323-237-01)
- 63323-237 - Cefazolin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 63323-237-10 identifies a specific commercial package of 25 vial in 1 carton / 3 ml in 1 vial (63323-237-01) of Cefazolin, a human prescription drug labeled by Fresenius Kabi Usa, Llc. This powder, for solution is formulated for intramuscular; intravenous use and contains cefazolin sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Fresenius Kabi Usa, Llc on July 15, 2011. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Cefazolin is an antibiotic used to treat a wide variety of bacterial infections. It may also be used before and during certain surgeries to help prevent infection. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria.
How is this Fresenius Kabi Usa, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 63323023710. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.